Publicaciones en las que colabora con PEDRO PABLO ESPAÑA YANDIOLA (59)

2024

  1. Basic host response parameters to classify mortality risk in COVID-19 and community-acquired pneumonia

    Scientific reports, Vol. 14, Núm. 1, pp. 12726

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  3. Impact of outdoor air pollution on severity and mortality in COVID-19 pneumonia

    Science of the Total Environment, Vol. 894

  4. Impact of prior SARS-COV-2 infection and vaccination on COVID-19 hospital admission and mortality amongst nursing home residents

    Aging Clinical and Experimental Research, Vol. 35, Núm. 8, pp. 1771-1778

  5. Impact of severe lymphopenia on the early prediction of clinical outcome in hospitalized patients with pneumococcal community-acquired pneumonia

    Infection, Vol. 51, Núm. 5, pp. 1319-1327

  6. Is the long-term mortality similar in COVID-19 and community-acquired pneumonia?

    Frontiers in Medicine, Vol. 10

  7. Leukocyte differential and cell population data in the evaluation of SARS-CoV-2 and other infections

    Journal of Laboratory and Precision Medicine, Vol. 8

  8. Pneumococcal Serotypes Associated with Community-Acquired Pneumonia Hospitalizations in Adults in Spain, 2016–2020: The CAPA Study

    Microorganisms, Vol. 11, Núm. 11

  9. Short- and long-term prognosis of patients with community-acquired Legionella or pneumococcal pneumonia diagnosed by urinary antigen testing

    International Journal of Infectious Diseases, Vol. 134, pp. 106-113

2022

  1. Author Correction: Machine learning-based model for prediction of clinical deterioration in hospitalized patients by COVID 19 (Scientific Reports, (2022), 12, 1, (7097), 10.1038/s41598-022-09771-z)

    Scientific Reports

  2. COVID-19 in young and middle-aged adults: predictors of poor outcome and clinical differences

    Infection, Vol. 50, Núm. 1, pp. 179-189

  3. Comparison of the prognostic performance of the CURB-65 and a modified version of the pneumonia severity index designed to identify high-risk patients using the International Community-Acquired Pneumonia Collaboration Cohort

    Respiratory Medicine, Vol. 200

  4. Detailed stratified GWAS analysis for severe COVID-19 in four European populations

    Human Molecular Genetics, Vol. 31, Núm. 23, pp. 3945-3966

  5. Early Recognition of Low-Risk SARS-CoV-2 Pneumonia: A Model Validated With Initial Data and Infectious Diseases Society of America/American Thoracic Society Minor Criteria

    Chest, Vol. 162, Núm. 4, pp. 768-781

  6. Estimating the risk of bacteraemia in hospitalised patients with pneumococcal pneumonia

    Journal of Infection, Vol. 85, Núm. 6, pp. 644-651

  7. Utility of Differential White Cell Count and Cell Population Data for Ruling Out COVID-19 Infection in Patients With Community-Acquired Pneumonia

    Archivos de Bronconeumologia, Vol. 58, Núm. 12, pp. 802-808

2021

  1. Checking Siblings of Patients with Idiopathic Pulmonary Fibrosis as a Scheme for Early Disease Detection

    Annals of the American Thoracic Society

  2. Correction to: Impact of reducing the duration of antibiotic treatment on the long-term prognosis of community acquired pneumonia (BMC Pulmonary Medicine, (2020), 20, 1, (261), 10.1186/s12890-020-01293-6)

    BMC Pulmonary Medicine

  3. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477